All results
1 results for impact
-
DOTS (20-0002)
This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of…
- Ages
- 18 Years - 99 Years
- Sexes
- All